Items Tagged ‘MPDL3280A’

February 26th, 2015

FDA Grants Breakthrough Therapy Designation for MPDL3280A, an anti-PDL1 Investigational Cancer Immunotherapy for Non-Small Cell Lung Cancer

By

The investigational cancer immunotherapy MPDL3280A (anti-PDL1) has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA). The designation was granted for the treatment of people with PD-L1 (Programmed Death-Ligand 1) positive non-small cell lung cancer (NSCLC) whose disease has progressed during or after platinum-based chemotherapy. Lung cancer remains the leading cause of […]

View full entry

Tags: anti-PDL1, Breakthrough Therapy Designation, Lung Cancer, Lung Cancer - Non-Small Cell, MPDL3280A, News, non-small cell lung cancer, nsclc, PDL1, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


June 12th, 2014

Experimental Drug Shows Promise for Treatment of Metastatic Bladder Cancer

By

According to results of a Phase I trial presented at the 2014 annual meeting of the American Society of Clinical Oncology, an investigative drug, MPDL3280A, demonstrates promise for the treatment of PD-L1 positive metastatic bladder cancer. Bladder cancer is diagnosed in roughly 50,000 men and 17,000 women annually in the United States. Bladder cancer is the […]

View full entry

Tags: Bladder Cancer, MPDL3280A, News, PD-L1, Recurrent Bladder Cancer, Stage IV/Metastatic Bladder Cancer